JOURNAL OF CLINICAL ONCOLOGY

简称 J CLIN ONCOL ·UNITED STATES ·出版周期 Biweekly ·年均收录 478 篇

41.9

最新影响因子

3.80%

自引率

约20%

投稿难度

平均2月

审稿周期

期刊简介

JOURNAL OF CLINICAL ONCOLOGY（ISSN号0732-183X）是一本由美国临床肿瘤学会（ASCO）出版的权威医学期刊，出版周期为周刊，出版地在美国，出版商为American Society of Clinical Oncology。该杂志的影响因子较高，属于SCI收录期刊，且在中科院分区中通常位于医学领域的1区或2区。它不是完全开放获取（OA）期刊，但部分文章可选择OA模式发表。杂志的发文特点集中于临床肿瘤学领域，涵盖癌症的诊断、治疗、预防及转化研究，尤其注重多学科协作和循证医学的临床实践。其研究领域包括但不限于临床试验、肿瘤生物学、免疫治疗、靶向治疗和患者生活质量等。杂志的质量较高，以严格的同行评审和高质量的原创研究著称，但投稿竞争激烈，拒稿率较高，且作为临床导向期刊，基础研究类文章可能较难被接收。总体而言，该杂志是肿瘤学领域的顶级期刊，具有较高的学术影响力和临床参考价值。

影响因子趋势

近期发表

Sustaining High Reliability Amid Artificial Intelligence Adoption in Oncology 2026-06-17

He Was Always There 2026-07-28

Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study) 2026-03-04

Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer 2026-07-27

Erratum: Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions 2026-08-14

COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600–Mutant Advanced Melanoma 2026-08-12

Role of Risk-Reducing Bilateral Mastectomy in BRCA1 and BRCA2 Pathogenic Variant Carriers 2026-07-09

Oncology Drug Development: Challenges of Increasingly Available Therapies 2026-03-04

Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study 2026-07-13

Reply to: Olaparib in Metastatic Breast Cancer: The Impact of Prior Cyclin-Dependent Kinase 4 and 6 Inhibitor Exposure on Efficacy 2026-07-07